How Blood Banks Screen for Infectious Diseases — The Testing Process Explained
By Alnoor Diagnostic Centre | Shadman, Lahore
The Science That Makes Blood Transfusion Safe
Every unit of donated blood that reaches a patient in Lahore has passed through one of the most rigorous safety screening processes in modern medicine. Before any donated blood is released for clinical use, it undergoes a comprehensive battery of laboratory tests designed to detect infectious agents that could be transmitted to a recipient through transfusion. This testing is not a single check — it is a layered system of multiple technologies applied simultaneously, each designed to catch what the others might miss.
Understanding how this screening process works gives blood donors and recipients alike an appreciation of the science protecting every transfusion — and explains why modern blood transfusion, once genuinely dangerous, has become extraordinarily safe in properly managed blood banking systems.
Why Screening Is Essential — The Risk Without Testing
Before systematic infectious disease screening was introduced into blood banking, transfusion-transmitted infections were a serious and common consequence of receiving donated blood. HIV, hepatitis B, and hepatitis C were transmitted through blood transfusions in significant numbers before the agents responsible were identified and tests developed to detect them. The introduction of systematic screening transformed transfusion medicine from a practice carrying meaningful infection risk into one with a residual risk measured in fractions of a million.
The fundamental challenge of blood screening is that donated blood frequently comes from individuals who are infected but do not yet know it — either because they are in the early window period before symptoms develop or because their infection produces no symptoms at all. An infected donor who feels completely healthy can unknowingly donate blood carrying a dangerous pathogen. The entire purpose of the screening system is to identify these donations before they reach a patient.
The Window Period — The Central Challenge in Blood Screening
The window period is the interval between the moment a person becomes infected and the moment current tests can reliably detect that infection. During this window, an infected individual may test negative on standard screening tests despite being genuinely infectious. The existence of this window period is the primary reason that modern blood banks layer multiple testing technologies rather than relying on a single test — and why donor selection and deferral criteria exist alongside laboratory testing as a complementary safety layer.
Different pathogens have different window periods. HIV has a window period of approximately nine to eleven days with modern nucleic acid testing. Hepatitis B has a longer window period of around twenty to sixty days. Hepatitis C window period is approximately seven to twenty-one days with NAT testing. Understanding these windows explains why even perfect testing cannot achieve zero residual risk — only reduce it to vanishingly small levels.
Serological Testing — Detecting Antibodies and Antigens
The foundation of blood bank infectious disease screening is serological testing — laboratory methods that detect either antibodies produced by the immune system in response to infection or antigens — proteins from the pathogen itself — present in the blood.
For HIV, modern screening uses fourth-generation combination assays that simultaneously detect both HIV antibodies and the p24 antigen — a protein from the HIV core that appears in the blood during early infection before antibodies have developed. This combination approach significantly reduces the HIV window period compared to antibody-only tests used in earlier generations of screening technology.
For hepatitis B, the primary screening target is the hepatitis B surface antigen — HBsAg — a protein on the outer surface of the virus that appears early in infection and persists in chronic carriers. Hepatitis B core antibody testing is added in many blood banking systems to capture donations from individuals with resolved infection who may nonetheless carry occult low-level hepatitis B in their blood.
For hepatitis C, antibody testing detects the immune response to HCV infection. Because the hepatitis C antibody window period is longer than the corresponding NAT window period, antibody testing is always combined with nucleic acid testing in modern blood banking practice.
Syphilis screening uses serological tests detecting antibodies against Treponema pallidum — the bacterium causing syphilis. A reactive syphilis test results in donor deferral and unit discard regardless of whether active infection is present, because reactive serology indicates either current infection or a history of infection that requires investigation.
Nucleic Acid Testing — Detecting the Pathogen Directly
Nucleic acid testing — NAT — represents the most significant advance in blood safety screening of the past three decades. Rather than detecting the immune system’s response to infection, NAT detects the genetic material — DNA or RNA — of the pathogen itself. Because viral genetic material appears in the blood almost immediately after infection, before the immune response has had time to generate detectable antibodies or even before antigen levels are high enough for serological detection, NAT dramatically compresses the window period.
For HIV, NAT reduces the window period from approximately sixteen to eighteen days with fourth-generation serological testing to approximately nine to eleven days. For hepatitis C, NAT compresses the window period from sixty to seventy days with antibody testing alone to approximately seven to twenty-one days. These reductions translate directly into fewer window-period donations reaching patients.
NAT is typically performed using multiplex assays that screen for HIV, HCV, and HBV simultaneously in a single test, using a pooled testing approach where samples from multiple donations are combined and tested together for efficiency. When a pool tests reactive, individual samples within it are tested separately to identify the specific reactive donation.
Malaria and Regional Pathogens
In Pakistan, where malaria remains endemic, blood banks apply specific measures to address the risk of transfusion-transmitted malaria. Plasmodium — the malaria parasite — can survive in donated red blood cells and cause severe malaria in immunocompromised transfusion recipients who have no natural immunity.
Donor questioning and deferral of individuals with recent malaria symptoms or travel history to endemic areas is the primary prevention strategy, supplemented by serological testing for malaria antibodies in higher-risk settings. Dengue virus — also endemic in Pakistan — has attracted increasing attention as a transfusion-transmitted pathogen, particularly during outbreak periods when asymptomatic viraemia in donors can be significant.
Quality Control and Residual Risk
The residual risk of transfusion-transmitted infection after comprehensive screening — combining serological testing, NAT, and donor selection — is extraordinarily small in well-managed blood banking systems. Modern estimates place the residual risk of HIV transmission from a screened blood unit at less than one in a million. Hepatitis C residual risk is similarly low. These numbers reflect decades of progressive improvement in testing sensitivity and the layered safety approach that characterises contemporary blood banking.
No system achieves zero risk — the window period means a small irreducible residual risk will always exist. But the combination of careful donor selection, comprehensive serological testing, and nucleic acid detection has made the modern blood supply safer than any point in the history of transfusion medicine.